Kidney Cancer Clinical Trial
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
Summary
The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.
Eligibility Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Advanced Renal Cell Carcinoma
Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
Must have at least 1 lesion with measurable disease
Exclusion Criteria:
Subjects with active central nervous system metastases
Subjects who received prior therapy with checkpoint inhibitor
Subjects with active, known or suspected autoimmune disease
Other protocol defined inclusion/exclusion criteria could apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
Jacksonville Florida, 32256, United States
Iowa City Iowa, 52242, United States
Charlotte North Carolina, 28204, United States
Pittsburgh Pennsylvania, 15212, United States
Waratah New South Wales, 2298, Australia
Westmead New South Wales, 2145, Australia
Herston Queensland, 4029, Australia
Elizabeth Vale South Australia, 5112, Australia
Malvern Victoria, 3144, Australia
Santiago Metropolitana, 75009, Chile
Recoleta Santiago De Chile, , Chile
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.